Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours

(131)I-metaiodobenzylguanidine ((131)I-MIBG) is a licensed palliative treatment for patients with metastatic neuroendocrine tumours. We have retrospectively assessed the consequences of (131)I-MIBG therapy in 48 patients (30 gastroenteropancreatic, 6 pulmonary, 12 unknown primary site) with metastat...

Descripción completa

Detalles Bibliográficos
Autores principales: Nwosu, A C, Jones, L, Vora, J, Poston, G J, Vinjamuri, S, Pritchard, D M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275478/
https://www.ncbi.nlm.nih.gov/pubmed/18283308
http://dx.doi.org/10.1038/sj.bjc.6604273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275478/
https://www.ncbi.nlm.nih.gov/pubmed/18283308
http://dx.doi.org/10.1038/sj.bjc.6604273

Ejemplares similares